SCYNEXIS to Present on Screening Technology Used in Anti-Malarial Research at ACS National Meeting
RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 08/20/12 -- SCYNEXIS, Inc. announces the presentation of innovative screening approaches used in the discovery of promising anti-malarial therapies at the American Chemical Society's (ACS) national meeting
Paul J. Kowalczyk, Ph.D., senior computational chemist in the company's Integrated Parasitology division, will make the presentation titled, "Machine learning: Better practices applied to anti-malarial drug discovery." The presentation will be Wednesday Aug. 22, from 2:05-2:50 p.m. at the ACS' 244th National Meeting & Exposition in Philadelphia at the Pennsylvania Convention Center. The oral presentation is scheduled during the Perspective in Applied Computational Methods session.
With more than 164,000 members, the ACS is the world's largest scientific society and one of the world's leading sources of authoritative scientific information. A nonprofit organization, chartered by Congress, ACS is at the forefront of the evolving worldwide chemical enterprise and the premier professional home for chemists, chemical engineers and related professions around the globe.
SCYNEXIS' Kowalczyk will present sets of better practices for eight machine learning methods and the creation of a platform on which different compounds can be tested. It is the first truly reproducible research in the area of chemical informatics applied to drug discovery research, enabling the results to be easily verified. The SCYNEXIS platform also eliminates the need to share proprietary intellectual property while advancing potential treatments for so-called neglected diseases like malaria by testing multiple compounds against the same platform.
SCYNEXIS has been involved for years in joint research for screening potential treatments for neglected diseases such as malaria and sleeping sickness.
The company has also developed a robust screening platform for the assessment of compounds against parasite species relevant to neglected tropical diseases. The platform was designed to identify compounds with potential activity in the areas of human and public health.
About SCYNEXIS, Inc.
SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed a proprietary cyclophilin inhibitor pipeline for the treatment of a broad range of diseases, including HCV and inflammation. www.scynexis.com.